Cargando…
Circulating tumour-derived KRAS mutations in pancreatic cancer cases are predominantly carried by very short fragments of cell-free DNA
BACKGROUND: The DNA released into the bloodstream by malignant tumours· called circulating tumour DNA (ctDNA), is often a small fraction of total cell-free DNA shed predominantly by hematopoietic cells and is therefore challenging to detect. Understanding the biological properties of ctDNA is key to...
Autores principales: | Zvereva, Maria, Roberti, Gabriel, Durand, Geoffroy, Voegele, Catherine, Nguyen, Minh Dao, Delhomme, Tiffany M., Chopard, Priscilia, Fabianova, Eleonora, Adamcakova, Zora, Holcatova, Ivana, Foretova, Lenka, Janout, Vladimir, Brennan, Paul, Foll, Matthieu, Byrnes, Graham B., McKay, James D., Scelo, Ghislaine, Le Calvez-Kelm, Florence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251242/ https://www.ncbi.nlm.nih.gov/pubmed/32249202 http://dx.doi.org/10.1016/j.ebiom.2019.09.042 |
Ejemplares similares
-
KRAS mutations in blood circulating cell-free DNA: a pancreatic cancer case-control
por: Le Calvez-Kelm, Florence, et al.
Publicado: (2016) -
Needlestack: an ultra-sensitive variant caller for multi-sample next generation sequencing data
por: Delhomme, Tiffany M, et al.
Publicado: (2020) -
Integrative Genome-Wide Gene Expression Profiling of Clear Cell Renal Cell Carcinoma in Czech Republic and in the United States
por: Wozniak, Magdalena B., et al.
Publicado: (2013) -
Urinary TERT promoter mutations are detectable up to 10 years prior to clinical diagnosis of bladder cancer: Evidence from the Golestan Cohort Study
por: Hosen, Md Ismail, et al.
Publicado: (2020) -
Urinary TERT promoter mutations as non-invasive biomarkers for the comprehensive detection of urothelial cancer
por: Avogbe, Patrice Hodonou, et al.
Publicado: (2019)